GENET archive

[Index][Thread]

4-Patents: Philip Morris secures patents on tobacco genes and plants



-----------------------
genet-news mailing list
-----------------------

-------------------------------- GENET-news --------------------------------

TITLE:  Philip Morris Betting on Genetic Breakthroughs from Tobacco Plant
        Research
SOURCE: The News & Observer - Knight Ridder/Tribune Business News, USA
        by Catherine Clabby
        http://sites2.stripes.devsf.stockpoint.com/cepmagazine/
        13story.asp?Mode=&Story=20030117/017e0436.xml
DATE:   Jan 17, 2003

------------------ archive: http://www.gene.ch/genet.html ------------------


Philip Morris Betting on Genetic Breakthroughs from Tobacco Plant Research

Jan 17, 2003 (The News & Observer - Knight Ridder/Tribune Business News via 
COMTEX) -- When Philip Morris USA agreed to give N.C. State University 
scientists $17.6 million to map the genes in tobacco plants, the company 
bought access to any breakthroughs it finds useful.

The nation's largest cigarette maker will share licenses to any patents 
generated by the mapping study. Philip Morris also gets first dibs on 
negotiating exclusive licenses.

No one can guarantee that identifying genes will yield new, blockbuster 
tobacco products. But the cigarette industry clearly sees commercial 
promise in tobacco's genetic blueprint.

"This is one of the many tools in the toolbox that will get us where we 
want to go," Philip Morris spokeswoman Jennifer Golisch said.

One state cigarette maker already is diving in. Vector Tobacco, based 
outside Roxboro, is on the verge of launching a new brand of ultra-low 
nicotine smokes made with genetically altered leaf invented at NCSU in the 
1990s.

By the end of the month, Vector is to introduce Quest, cigarettes with 
three increasingly lower nicotine levels, in seven northern states. Quest's 
very existence can be traced to a NCSU genetics lab.

In the 1980s, Mark Conkling, then a N.C. State plant geneticist, grew 
fascinated with a bunch of genes that seemed active only in the roots of 
tobacco. In time he focused on one gene: NiQPT1. It plays a key role in 
producing nicotine, a natural pesticide that normally moves from the 
plant's roots to its leaves.

In the 1990s, a N.C. State plant breeder approached Conkling about a small 
New York company's interest in breeding tobacco without nicotine. 
Traditional breeding would take years. Instead, Conkling's lab used an 
altered form of the gene to bio-engineer a new plant with nearly no 
nicotine. The small firm licensed the technology.

In time, Vector's parent company licensed the technique. Conkling went to 
work for Vector. And Quest went into development.

"Tobacco is easy to genetically modify," Conkling said. "It's one of the 
easiest plants to add genes to."

Philip Morris has said it wants to make less-dangerous cigarettes, possibly 
using genetic engineering. But, citing "business proprietary" reasons, the 
company won't discuss specific products it envisions from research at N.C. 
State or elsewhere, Golisch said.

H&R Block Financial Analyst Kelly Capaldi, who watches the tobacco 
industry, says all cigarette companies would be more likely to make 
products with genetically altered leaf if giant Philip Morris did. "If they 
ever released a product, you'd see copycats," she said.

Now vice president of genetics research at Vector Tobacco, Conkling said 
understanding all genes active in tobacco opens up new avenues for the 
industry.

Scientists know a lot about some of the scores of carcinogenic chemicals in 
tobacco smoke. With genetic re-engineering, they may be able to reduce 
their production, Conkling said.

Genetic tinkering could make tobacco plants more resistant to pests or 
easier to shred, Conkling said. Biotechnology gurus still believe 
genetically altered tobacco could be used to grow new products to open new 
markets to tobacco farmers. "There are a number of possibilities out 
there," he said.

Obstacles abound, too.

Some tobacco farmers have rejected farming bio-engineered tobacco, in part 
because European markets don't like those crops.

Early on, Vector executives said they saw Quest as a smoking-cessation aid. 
But Vector can't market Quest 1, 2 and 3 as such without FDA approval. 
Vector can't seek that approval until it has evidence the product is safe 
and effective.

Instead, Vector is pitching Quest as a product that can help smokers "step 
down" from nicotine. And it hopes the brand will be more successful than 
its first and not-yet successful venture: Omni.

Vector Tobacco is a sister company to Liggett Group, the former downtown 
Durham company that now makes mostly discount cigarettes in Mebane. The 
company was launched to use science to develop less risky cigarettes.

In 2001, Vector launched Omni, a cigarette advertised as a less-
carcinogenic smoke due to some chemical adjustments and a newfangled 
filter. It hasn't sold well.

Vector Tobacco won't give out sales numbers. But it says its efforts to 
introduce and sell "potentially" reduced risk cigarettes lost

$20.2 million in the third quarter of 2002.

Still, Vector is moving on Quest.

"Quest offers smokers a new alternative and demonstrates the increasing 
role that technology has on the marketplace," said James Taylor, senior 
vice president of marketing for Liggett Vector brands.

Only time -- and sales numbers -- will tell.